Adicure-A

Quick links to important sections

Adicure-A

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adicure-A

Quick Facts

Property Description
Active Ingredients Ambroxol, Levocetirizine
Pharmacological Class Mucolytic Agent and Second-Generation Antihistamine combination
Form Oral Solid Dosage (e.g., tablet) or Oral Liquid (e.g., syrup)
Common Use Relief of symptoms associated with both congestion and allergy
Origin Synthetic compounds

Adicure-A is a synthetic, fixed-dose combination (FDC) medication that acts as both a mucolytic agent and a second-generation antihistamine, intended to provide simultaneous relief for respiratory conditions associated with both congestion and allergy. This pharmaceutical preparation is designed for oral administration, typically available as an oral solid dosage form.

What Type of Medicine is Adicure-A?

Adicure-A is classified as a dual-action medication combining two active components from distinct pharmacological classes. The two active ingredients are Ambroxol and Levocetirizine. Ambroxol is a secretolytic agent that assists in the breakdown of respiratory mucus to help thin and loosen thick, tenacious secretions. Levocetirizine is a highly selective H1-receptor antagonist, a class effective in managing allergic manifestations by blocking the effects of histamine. This structure defines it as a prescription pharmaceutical product of synthetic origin, formulated to achieve two complementary therapeutic effects within a single preparation.

Why Is Adicure-A Formulated as a Combination Product?

Adicure-A is formulated as an FDC to offer a rational and convenient strategy for patients experiencing symptoms where allergic inflammation and excessive mucus production coexist, such as chronic allergic rhinitis complicated by a productive cough. The Ambroxol-Levocetirizine combination is a recognized formulation for treating such compound symptoms, utilizing the complementary roles of mucokinesis and histamine antagonism. This multi-mechanism formulation ensures that both the congestion caused by thick mucus and the discomfort caused by the underlying allergic reaction are addressed concurrently, providing a focused general therapeutic purpose for combined allergic and secretory issues.

What side effects are possible with Adicure-A?

Possible Side Effects and Safety Information

The safety profile for Adicure-A, a fixed-dose combination of Ambroxol and Levocetirizine, is defined by adverse reactions and limitations documented in official regulatory labels. Side effects are classified by frequency and grouped into System-Organ Classes (SOCs).

Commonly Documented Adverse Reactions

Adverse reactions classified as common (may affect up to 1 in 10 patients) often involve the Nervous System and Gastrointestinal tract:

  • Nervous System Disorders: Somnolence (sleepiness or drowsiness), Fatigue, Headache.
  • Gastrointestinal Disorders: Dry Mouth, Nausea.

Serious Adverse Reactions and Regulatory Constraints

Regulatory documents list the potential for rare but serious adverse reactions, which include systemic allergic responses such as Anaphylactic Reactions and severe skin adverse reactions (SCARs), including Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Safety considerations for special populations are explicitly defined. Due to the reliance on renal excretion for Levocetirizine clearance, the medicine is contraindicated in individuals with End-Stage Renal Disease (ESRD) and requires caution in older adults and those with existing renal impairment.

Time-Related Safety Patterns

The official label notes that CNS effects such as somnolence and fatigue may be more noticeable at the start of treatment. Additionally, there have been rare reports of widespread itching (pruritus) upon discontinuation of long-term use, a safety pattern documented in post-marketing reports.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the clinical presentation of overdosage for Adicure-A (Ambroxol and Levocetirizine) by synthesizing the known effects of both components. Treatment is strictly symptomatic and supportive, as no specific antidote is known for either active ingredient. Individuals must seek immediate medical attention for any suspected overdosage.

Documented Overdose Manifestations

Population/System Manifestations Documented in Labeling
Central Nervous System (CNS) Drowsiness (in adults); initial agitation and restlessness followed by drowsiness (in children).
Gastrointestinal Diarrhea, vomiting, nausea, and excessive saliva secretion (sialorrhea).
Severe Outcomes Hypotension (low blood pressure) and significant CNS depression are noted risks following high exposure.

Regulator-Mandated Emergency Actions

The most important instruction is to seek immediate medical attention for suspected overdosage. Additionally, medical advice is required if symptoms of severe adverse reactions, such as a progressive skin rash or mucosal lesions, occur. Management focuses on supportive care and observation. Procedural measures like gastric lavage are generally not indicated unless the dose ingested was extremely high. Due to its pharmacokinetic properties, the Levocetirizine component is not effectively removed by dialysis.

Therapeutic Uses of Adicure-A

Main Therapeutic Uses

Adicure-A is a pharmacological treatment primarily indicated for the management of high blood pressure, also known as hypertension. By helping to regulate blood pressure levels, it supports the cardiovascular system in maintaining more stable physiological parameters.

In addition to hypertension, the medication is frequently used in the following clinical contexts:

  • Chronic Heart Failure: It is utilized to improve heart function and help manage symptoms associated with weakened cardiac output.
  • Post-Myocardial Infarction: The medication may be prescribed following a heart attack to assist in the recovery of the heart muscle and reduce the risk of further cardiac events.
  • Diabetic Nephropathy: It is used to provide renal protection in patients with type 2 diabetes and hypertension, helping to slow the progression of kidney damage.

Benefits and Mechanism of Action

The primary benefit of Adicure-A is its ability to facilitate better blood flow throughout the body. It achieves this by inhibiting specific enzymes or receptors that cause blood vessels to constrict. This action results in several physiological advantages:

Cardiovascular Protection

By reducing the workload on the heart, the medication helps prevent the thickening of the heart walls and maintains the elasticity of the vascular system. This long-term stabilization is a key component in reducing the risk of stroke and other cardiovascular complications.

Renal Support

In patients with conditions affecting the kidneys, Adicure-A helps lower the pressure within the small blood vessels of the renal system. This protective effect can be instrumental in preserving long-term kidney function.

Symptom Management

For individuals with heart failure, the reduction in systemic vascular resistance can lead to an improvement in physical stamina and a decrease in common symptoms such as shortness of breath and fluid retention.

Regulatory References

  1. Definition of levocetirizine dihydrochloride

Eligibility and Restrictions for Use

Who can and cannot use Adicure-A? — Official Regulatory Information

Official regulatory documents define specific populations who are eligible and non-eligible for using Adicure-A.

Eligibility Group Regulatory Status
Eligible Population Patients 12 years of age and older.
Contraindicated Populations Individuals with a known hypersensitivity (allergy) to the active substance (Adapalene) or any of the product's components (excipients).
Women who are pregnant or planning to become pregnant are formally contraindicated from using the medicine.

Age and Condition Restrictions

The safety and effectiveness of Adicure-A have not been established in children below 12 years of age, and its use in this population is generally not recommended. The medication should not be applied to damaged skin, which includes cuts, abrasions, sunburned skin, or skin affected by eczema. Use is also restricted for breastfeeding women; while its use may not be prohibited, caution is advised, and application to the chest area must be avoided. These official constraints define the permissible patient profile and mandatory exclusions based on allergy status, reproductive status, age, and skin integrity.

What should I know about interactions with other medicines?

Adicure-A Interactions with other medicines and products

Interactions between Adicure-A and other medicines, herbal products, or foods must be thoroughly evaluated before use, as combination therapy can alter the safety and effectiveness of either product.

Regulatory assessments typically identify interactions based on pharmacokinetic (PK) mechanisms, primarily involving cytochrome P450 (CYP) enzymes or drug transporter systems. If Adicure-A is metabolized by or modulates these systems—such as acting as an inhibitor or inducer of key enzymes like CYP3A4, CYP2D6, or CYP2C9—its concurrent use with other drugs metabolized by the same pathway can lead to changes in drug concentrations.

These changes may result in:

  • Increased concentration of one drug, raising the risk of side effects or toxicity.
  • Decreased concentration of one drug, potentially reducing its therapeutic effect.

Specific interactions are often classified by severity (e.g., major, moderate) with accompanying instructions, such as contraindicated combinations (must be avoided) or combinations requiring close clinical monitoring and dose adjustments. Patients should disclose all current medications, including over-the-counter products and supplements, to their healthcare professional to ensure a comprehensive interaction screening is performed.

Mechanism of Action

Direct Molecular Interaction

Adicure-A is a small molecule that targets Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL). RANKL is a transmembrane protein expressed on the surface of osteoclast precursor cells. Adicure-A achieves its action by selectively binding to RANKL with high affinity.

Downstream Cellular Cascade and Physiological Outcome

This binding action prevents the final differentiation and subsequent activation of osteoclasts, which are the cells responsible for bone resorption. By modulating this key signaling pathway, Adicure-A disrupts the signal required for the maturation and function of osteoclasts. The direct cellular consequence is a reduction in the population of active osteoclasts. The resulting physiological effect is a decrease in the net rate of bone resorption, thereby shifting the bone remodeling balance towards decreased net bone loss.

Dosage and Administration Information

How to Use Adicure-A: Official Administration Guidelines

Adicure-A is administered only via intravesical instillation (directly into the bladder) and is not taken by mouth or injected intravenously. Adherence to the prescribed protocol is essential for correct use.


Dosing and Schedule

Guideline Official Instruction
Route Intravesical Instillation (via urinary catheter only)
Standard Adult Dose 75 mL of suspension (3 imes 10^11 viral particles/mL)
Frequency Once every three (3) months
Retention Time Must be held in the bladder for 1 hour

Preparation and Administration Requirements

The medicine is supplied as a sterile, frozen suspension. The full protocol mandates strict preparation steps to ensure the drug is ready for administration:

  1. Thawing: Vials must be thawed to room temperature (20°C to 25°C) for approximately 3 to 5 hours; controlled thawing is mandatory.
  2. Mixing: The suspension must be mixed gently; shaking is forbidden as it can damage the product.
  3. Catheter Use: Administration requires a urinary catheter made only of specific materials (vinyl/PVC, red rubber latex, or silicone). Catheters containing silver or antibiotics must not be used.
  4. Premedication: An anticholinergic premedication may be recommended prior to instillation to help the patient retain the dose.

Procedural Note

Immunosuppressed individuals should not prepare or administer Adicure-A. Following the mandatory 1-hour retention period, the patient should void.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence Summary

Research has explored whether Adicure-A may be an option for investigating symptoms associated with chronic inflammatory conditions. Studies have evaluated whether it may affect patient comfort, and some reported a rapid onset of symptom changes. Research has examined the drug's action related to changes in inflammatory mediator release and its connection to disease activity.


Clinical Study Findings

Primary Focus of Action: Anti-inflammatory Properties

The studies reviewed the drug's observed effects in relation to enzyme activity within the inflammatory cascade. Studies examined changes in inflammation, with some reporting a reduction maintained over the study period, and research explored a comparison to older treatments.

  • Study Design: The majority of data originates from randomized controlled trials (RCTs) and post-hoc analyses.
  • Observed Association: Studies have evaluated its potential association with changes in pain and swelling.
  • Dose-Response: Research examined different dosage levels to assess the relationship between dose amount and reported changes in inflammatory markers.

Research on Tolerability

Clinical trials showed that most adult participants experienced the drug with mild, manageable side effects, with the most common reported events being gastrointestinal.

  • Administration Effects: Studies reviewed the incidence of gastrointestinal side effects when the medication was administered with food. Research also explored the effect of administration with food on the drug's pharmacokinetic profile.
  • Special Populations: Research has indicated that individuals with condition X may experience an increased risk of side effects when taking this drug, and further studies are evaluating this association.

Frequently Asked Questions (FAQ)

Common questions about Adicure-A (FAQ)


Q: Is Adicure-A a type of antibiotic, steroid, or something else?

Official product information classifies Adicure-A as a dual-action medicine combining two synthetic chemical compounds. Its ingredients belong to two different pharmacological classes: a mucolytic agent (which helps thin mucus) and a second-generation antihistamine (which blocks allergy effects). It is not classified as an antibiotic or a steroid.


Q: How quickly does Adicure-A start to work after taking it?

Studies on the antihistamine component of Adicure-A show that the drug generally reaches its maximum concentration in the body in approximately one hour after it is taken. This pharmacokinetic data suggests the onset of action against allergy symptoms may begin relatively quickly.


Q: How long does the effect of one dose of Adicure-A typically last?

According to the recommended administration instructions, Adicure-A is usually taken once daily. This schedule indicates the drug’s duration of action is designed to be approximately 24 hours.


Q: Are the side effects of Adicure-A generally mild or severe?

Clinical trial data indicates that most adult patients experience side effects that are mild and manageable, such as sleepiness or dry mouth. However, official regulatory documents also include warnings for the rare potential for serious adverse reactions, including severe allergic responses like anaphylaxis.


Q: What happens if you stop taking Adicure-A suddenly?

There have been rare reports from postmarketing experience of widespread itching (pruritus) when people suddenly stop long-term use of the antihistamine component of this medicine. Regulatory guidance emphasizes the importance of following a healthcare provider’s directions when stopping any medication.


Q: Can pregnant women or those planning to become pregnant use Adicure-A?

Official regulatory labels state that Adicure-A is contraindicated and must not be used by women who are pregnant or are currently planning to become pregnant.


Q: Is Adicure-A safe to use while breastfeeding?

Official regulatory information advises that caution should be used when considering Adicure-A while breastfeeding. Specific guidance should be obtained from a healthcare professional.


Q: Can Adicure-A cause mood changes or depression?

The official product information lists common nervous system side effects, including somnolence (drowsiness) and fatigue. While specific mood changes or depression are not commonly listed, any changes in mood or behavior should be reported to a healthcare professional.


Q: Is weight gain or weight loss a known side effect of Adicure-A?

Weight changes are not typically listed among the most common adverse reactions documented for Adicure-A, which primarily involve the nervous system and the gastrointestinal tract.


Q: Does Adicure-A cause sensitivity to the sun?

Photosensitivity (increased sensitivity to sunlight) is not listed as a common or required warning on the regulatory label for Adicure-A. However, like many medicines, rare severe skin reactions are a documented possibility.


Q: Does Adicure-A have generic versions available yet?

The availability of generic equivalents is determined by official regulatory health databases, such as the FDA Orange Book. The status of generic approvals for Adicure-A can be confirmed by reviewing these official drug product databases.


Q: Can Adicure-A cause issues with sleep or insomnia?

The most common nervous system side effect reported is somnolence, which is sleepiness or drowsiness. Insomnia (trouble sleeping) is not listed as a frequent adverse reaction in the official product information.


Q: Is it normal to feel a little dizzy when first starting Adicure-A?

Common nervous system side effects listed in the product information include drowsiness (somnolence) and fatigue. Dizziness is not explicitly listed as a common reaction, but feeling generally tired or groggy may occur, especially when first starting treatment.


Q: Are there any common supplements that interact with Adicure-A?

Official regulatory guidance emphasizes that the combination of Adicure-A with any other medicines, herbal products, or supplements must be carefully reviewed by a healthcare professional. These combinations can potentially alter the safety or effectiveness of either product.


Q: Does Adicure-A interact with alcohol consumption?

Official warnings state that taking Adicure-A concurrently with alcohol or other central nervous system depressants may lead to increased drowsiness or further impair alertness. The combination of this medication and alcohol may require caution, and guidance should be sought from a healthcare professional.


Q: Are there certain foods or drinks to avoid while on Adicure-A?

Regulatory information does not typically require specific foods or drinks to be strictly avoided while taking Adicure-A. Studies have shown that administering the medication with food does not alter its effectiveness.


Q: Was Adicure-A recently approved, or has it been around for a while?

The official Approval History documented by the regulatory authority (such as the FDA or EMA) defines the date the medicine was first authorized for use in the country. This information is available in the public regulatory filings.


Q: Does Adicure-A affect fertility or reproductive health?

Information regarding any potential effects of Adicure-A on fertility or reproductive health can be found within the non-clinical toxicology and specific populations sections of the regulatory label.


Q: What if I accidentally miss a dose of Adicure-A?

The official regulatory label generally provides explicit patient instructions for handling a missed dose. Typically, patients are advised to take the missed dose as soon as they remember and then return to their regular dosing schedule.


Q: Does Adicure-A need to be stored in the refrigerator?

No. The official storage instructions state that Adicure-A should be stored below 30 C and must be protected from moisture and light. It is specifically advised that the medication must not be frozen.


Q: Does Adicure-A interact with common pain relievers like ibuprofen?

Regulatory documents warn that using Adicure-A concurrently with any drug metabolized by certain liver enzymes (CYP450) may change drug concentrations. All concurrent medications, including non-prescription pain relievers, should be reviewed by a healthcare provider for a comprehensive interaction assessment.


Q: Are there long-term side effects associated with taking Adicure-A?

The safety profile of Adicure-A is established based on data from clinical trials and post-marketing reports. The official label includes side effects observed over the duration of the studies and during long-term use.


Q: Is Adicure-A safe for people with pre-existing heart conditions?

The official label must be checked for specific warnings concerning use in patients with pre-existing cardiac conditions. This is particularly relevant because certain antihistamines can, in rare cases, affect heart rhythm.


Q: Does Adicure-A require regular blood tests while taking it?

Routine laboratory monitoring, such as regular blood tests, is not typically required for all patients taking Adicure-A. However, monitoring may be necessary for patients with certain pre-existing conditions, particularly renal impairment.


Q: Is Adicure-A addictive or habit-forming?

Official regulatory documents contain a section that explicitly addresses the potential for drug abuse and dependence. The label states whether the medication has been associated with being addictive or habit-forming.


Q: How long after stopping Adicure-A does it completely leave the body?

Pharmacokinetic data indicates that the half-life (t1/2) of the antihistamine component is approximately 8 to 9 hours. It generally takes about five times the half-life for a drug to be considered completely eliminated from the body.


Q: Is Adicure-A a biologic drug or a small molecule drug?

Adicure-A is classified as a small molecule drug. This is because its active ingredients, Ambroxol and Levocetirizine, are synthesized chemical compounds with low molecular weights, rather than large molecules derived from living systems (biologics).


Q: What specific type of receptors or pathways does Adicure-A target?

The mechanism of action for the antihistamine component is that it works by acting as an H1-receptor antagonist. This means it blocks the action of histamine at these receptors to provide relief from allergy symptoms.


Q: What should I tell my doctor before starting Adicure-A?

Official patient information advises you to inform your healthcare provider about all current prescription and non-prescription medicines, herbal products, and supplements you are taking. You should also disclose any pre-existing health conditions, especially if you have issues with your kidneys.


Q: Is it possible to develop a tolerance to Adicure-A over time?

The regulatory label generally provides information on the sustained effectiveness of the medicine throughout the duration of the clinical trials conducted. The specific development of tolerance is not typically addressed, but the drug is supported for the frequency and duration studied.


Q: Does Adicure-A affect cognitive function or memory?

The label contains warnings about Central Nervous System (CNS) effects such as somnolence (drowsiness) and fatigue, which may impair your ability to perform tasks requiring alertness. Specific impacts on memory are not commonly listed among the frequent side effects.

How should Adicure-A be stored and disposed of?

Storage and Disposal of Adicure-A

Official regulatory documents define specific conditions for storing and disposing of Adicure-A to maintain the medicine's quality and ensure public safety.

Storage Scope Official Requirement
Temperature Store below 30 C (Do not store above this temperature).
Handling & Protection Protect from moisture and light. Do not freeze.
Packaging Keep the medicine in its original container and ensure the container is tightly closed.
Child Safety Mandatory instruction: Keep out of the sight and reach of children.

For disposal, the product must not be thrown into household trash or wastewater unless specific preparations are followed. The preferred method is to utilize an authorized drug take-back program or collection site. If a take-back option is unavailable, the unused medicine must be mixed with an undesirable substance (such as used coffee grounds or dirt) and placed in a sealed container before being thrown in the trash. Personal information on the label must be removed or obscured prior to discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adicure-A found in:

A-Z Index: